Oncolytics reports faster enrollment in REO 033 colorectal cancer studySep 30Regulatory decisionOncolytics BiotechSagimet Biosciences Inc.Updated
Oncolytics gets FDA feedback on pivotal path for pelareorep in colorectal cancerAug 18Regulatory decisionOncolytics Biotechpelareorep
Oncolytics wins FDA Fast Track for pelareorep in second-line anal cancerJul 20Regulatory milestoneOncolytics Biotechpelareorep
Sign inSign in